J&J Will Take $600 Million Charge to Pay for Lawsuits

Johnson & Johnson will set aside $600 million in the second quarter to increase its reserves for potential settlements of civil lawsuits alleging it illegally marketed drugs including the anti-psychotic Risperdal.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.